monoclonal antibody cancer trial is 100% successful
A recent study published in The New England Journal of Medicine has yielded groundbreaking results after a monoclonal antibody successfully eradicated rectal cancer in all enrolled patients, ushering them into complete remission without resorting to chemotherapy, radiation, or surgical interventions
Dr. Andrea Cercek, one of the lead researchers, said:
“It’s absolutely incredible. We didn’t expect it. We’ve certainly never seen this before.
It’s really what, you know, cancer doctors’ dreams are made of to see a response like this. Such incredible efficacy with really, almost no toxicity.”
Twelve patients participated, with a median age of 54 and 62 percent being women. These individuals had advanced rectal cancer, which typically requires harsh treatments.
Patients were administered dostarlimab, a specific type of monoclonal antibody, every three weeks for six months, avoiding the conventional, often debilitating treatments associated with their condition.
Every participant experienced complete clinical remission, with no trace of tumors detected through magnetic resonance imaging (MRI).
The authors wrote:
“A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up.
All 12 patients (100 percent; 95 percent confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging … and no cases of progression or recurrence had been reported during follow-up (range, six to 25 months after treatment).
No adverse events of grade 3 or higher have been reported.”
How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.
For more details, click here to read the study, or go here to watch the full video from The Epoch Times.
See more here vigilantfox
Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.
Jakie
| #
Is this chohencidence…that since it’s now become common knowledge that Fenbendazole, IVM & HCQ/Zinc are widespread Cancer cures…now these industry types do a put to show a money maker monoclonal antibody cres cancer too? They’re attempting to remain profitable and relevant…not likely after many decades of torturing the cancer public…when cures were already to hand.
….
Reply
Saeed Qureshi
| #
@ “Monoclonal Antibody Cancer Trial Is 100% Successful” So did mRNA vaccines for COVID-19, remember! “Science” by doctors. https://bioanalyticx.com/very-important/
Reply
Wisenox
| #
Everything cures cancer now, it’s crazy.
Calcium signaling, or as the WHO likes to tease, Ca+ (they know what’s going on). Beat that, and early onset drops off a cliff.
Reply